Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| I'm incredibly proud of our team of approximately 5,000 committed, mission-driven professionals worldwide who work so hard to help us collectively deliver what we promised to both shareholders and customers during a year when many in the industry faced headwinds |
| Looking ahead, today, we're providing a strong financial outlook for 2024, as well as reiterating confidence in our $300 million adjusted EBITDA run rate exit target for 2024 |
| I think the success we had in 2023 and our strong outlook for 2024 is driven by our diversification across Medicare, Medicaid, and commercial |
| We had another outstanding year achieving our profitability, cash flow, new business growth and operating goals for all of our stakeholders, and we remain focused on our mission of improving care for people with complex conditions |
| For the Performance Suite, the forecasted improvement is primarily driven by initial margin expansion of just over 10% on the over $400 million in Performance Suite revenue launched during 2023 and is consistent with what we experienced for '22 launches across 2023 |
| And certainly, some positive comments from you guys about the pipeline and the set-up to achieve that target |
| In addition, we have a strong mix between our Technology and Services and Performance Suite businesses |
| We wanted to quantify the PMPM around surgery, which we did in the script, just to give you a sense to your point of it's not immaterial what the opportunity is here just for surgery and radiation is also attractive, so this is -- you know, I think it's a real development for the company and will benefit us both on the Technology and the Performance Suite side |
| Cash flow is a critical component of our sustainable financial model, and we ended the fourth quarter in 2024 in a strong position ahead of where we anticipated due to exceptionally strong cash collections |
| Our pipeline also remains strong |
| And with the strong Q4, we ended the year at over $175 million on this metric |
| As a reminder, those principles are: One, strong organic growth |
| Within the Performance Suite, we continue to see strong results in line with our expectations |
| Our third investment theme is disciplined capital allocation, and in 2023 we made great strides in generating cash, de-levering the business and lowering our cost of debt financing |
| So we feel really good about the path to kind of closing that gap by the end of the year |
| I believe Q4 of '23 demonstrates the value of our balanced growth strategy with our cross-sell delivering growth in product members despite a quarter-over-quarter decline in unique members due to Medicaid redeterminations |
| On the top line, we are projecting full-year revenues of between $2.4 billion and $2.5 billion, representing approximately 25% organic growth at the midpoint, well ahead of our baseline mid-teens long-term outlook, and driven by continued strong uptake of our Performance Suite products |
| For example, looking at 2022 Performance Suite launches, we saw an improvement of over 10 percentage points in our margins between Q4 of '22 and Q4 of '23, consistent with our targets and the result of both initial actuarial conservatism and quality and cost improvements through our model |
| We believe this is an important agreement as it provides a path for us to bundle our radiation and surgical management capabilities and with our medical oncology in the Technology and Services Suite, creating a PMPM expansion opportunity for the future |
| We are pleased to be on-track with our profit targets as we exit the year, delivering adjusted EBITDA growth of almost 49% relative to Q4 of 2022 |
| One place we're seeing some strength is if you're traditional imaging customer, and that's what you had from an NIA perspective, and we have a conversation about the fact that we can incorporate imaging and genetics into a broader condition management model around cardiology or oncology, eventually around MSK, it's obviously just a better proposition for the member and for the plan to look at things holistically rather than just look at a given vertical like imaging, right? So I think that's one good example |
| Importantly, sitting here in February, we are now more than 50% of the way through this process and believe we have very good insight into how it is playing out |
| And so, across all of our Technology and Services arrangements where we have Med-Onc, I think that's a clear opportunity |
| On organic growth, we have consistently outperformed our new business targets, announcing an average of 11 new partners annually for the past three years versus a target of six to eight per year |
| Importantly, these headwinds are well understood and time-bound with the Administrative Services impact complete as we exit '23, while our core business drivers will continue to propel us towards our $300 million adjusted EBITDA exit run rate target for 2024 |
| Two, grow in profitability |
| We are pleased to have delivered this in a year where we were also investing heavily in integration and business restructuring to align our organization with our go-forward strategy in value-based specialty care |
| During 2023, we began to see progress because of the NIA acquisition that we believe increases Evolent's qualifications and competitiveness for large RFPs |
| Year-over-year, specialty care revenue grew approximately 74% versus a year ago, with the NIA acquisition contributing approximately 19% to reported growth |
| We feel high confidence in achieving them and they are contractual in nature |
| Statement |
|---|
| We ended the year with a gross Medicaid membership decline of 8.5% on a same-store basis compared to our forecast of 8% to 10% |
| First, we anticipate an approximate $4 million headwind to quarterly adjusted EBITDA from Medicaid redeterminations relative to Q4 of '23, which I'll discuss more in a bit |
| And we continue to forecast a total decline in the mid-teens by the middle of this year |
| And then you've got things like prior authorization and pressure on utilization management, hitting all payer types, including commercial |
| I think the second category, which is newer is around what I would call more acute medical loss ratio pressure, right, where payer A is underwriting pressure and has a gap to their goal for their fourth quarter of this year and beyond |
| And the commentary from many MCOs indicates elevated utilization during Q4, particularly for inpatients and supplemental benefit cost drivers |
| During 2023, this performance in our core business was offset in part by expected headwinds for Medicaid redeterminations and the runout of certain legacy Administrative Services clients during 2023 |
| John Johnson Had a tough time understanding you there, Jack |
| In Medicaid, representing 35% of our revenue, the primary question has been the impact of redeterminations on the top and bottom lines |
| In Medicare Advantage, representing about 42% of our revenue, the primary question has been elevated utilization |
| First, relative to cadence across the year, the performance overall, and then specific to your question on new business wins, as we look at EBITDA performance in '23 and compare to our key drivers in '24, one of the core observations that we would make is some of the headwinds that we experienced in '23 from the Administrative Services run out and Medicaid redeterminations are mostly now behind us, with a little bit to go on the Medicaid side |
| If you look at our work in oncology as an example, many health plans are struggling with the cost of cancer care with many seeing annual cost increases of over 10% |
| Obviously, some of the Medicaid plans getting hit with redetermination |
| We have found that many plans have increased their focus on specialty care management over the past six months, some citing the V28 Risk Adjustment changes and others because of general utilization pressures |
| Continuing at the same sales pace would likely get us beyond our year-end target |
| This statistic has been a useful directional indicator, but has also underrepresented our growth |
| Formally, it does increase it a little bit |
| As a result, the PMPMs will be lower than in oncology or cardiology, but we expect with the same general margin profile as our existing Performance Suite business |
| Nothing particularly structural |
Please consider a small donation if you think this website provides you with relevant information